Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 8/2018

01-08-2018 | Nephrology - Review

The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus

Authors: Mehmet Kanbay, Emine M. Onal, Baris Afsar, Tuncay Dagel, Aslihan Yerlikaya, Adrian Covic, Nosratola D. Vaziri

Published in: International Urology and Nephrology | Issue 8/2018

Login to get access

Abstract

Chronic kidney disease (CKD) has been shown to result in profound changes in the composition and functions of the gut microbial flora which by disrupting intestinal epithelial barrier and generating toxic by-products contributes to systemic inflammation and the associated complications. On the other hand, emerging evidence points to the role of the gut microbiota in the development and progression of CKD by provoking inflammation, proteinuria, hypertension, and diabetes. These observations demonstrate the causal interconnection between the gut microbial dysbiosis and CKD. The gut microbiota closely interacts with the inflammatory, renal, cardiovascular, and endocrine systems via metabolic, humoral, and neural signaling pathways, events which can lead to chronic systemic inflammation, proteinuria, hypertension, diabetes, and kidney disease. Given the established role of the gut microbiota in the development and progression of CKD and its complications, favorable modification of the composition and function of the gut microbiome represents an appealing therapeutic target for prevention and treatment of CKD. This review provides an overview of the role of the gut microbial dysbiosis in the pathogenesis of the common causes of CKD including hypertension, diabetes, and proteinuria as well as progression of CKD.
Literature
1.
Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489:220–230PubMedPubMedCentralCrossRef
2.
3.
Yoshifuji A, Wakino S, Irie J, Tajima T, Hasegawa K, Kanda T, Tokuyama H, Hayashi K, Itoh H (2016) Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol Dial Transplant 31:401–412PubMedCrossRef
4.
Wen L, Duffy A (2017) Factors influencing the gut microbiota, inflammation, and type 2 diabetes. J Nutr 147:1468s–1475sCrossRef
5.
Roesch LF, Lorca GL, Casella G, Giongo A, Naranjo A, Pionzio AM, Li N, Mai V, Wasserfall CH, Schatz D, Atkinson MA, Neu J, Triplett EW (2009) Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J 3:536–548PubMedPubMedCentralCrossRef
6.
Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J, Sahay B, Pepine CJ, Raizada MK, Mohamadzadeh M (2015) Gut dysbiosis is linked to hypertension. Hypertension 65:1331–1340PubMedPubMedCentralCrossRef
7.
Khoury T, Tzukert K, Abel R, Abu Rmeileh A, Levi R, Ilan Y (2017) The gut-kidney axis in chronic renal failure: a new potential target for therapy. Hemodial Int 21:323–334PubMedCrossRef
8.
Amdur RL, Feldman HI, Gupta J, Yang W, Kanetsky P, Shlipak M, Rahman M, Lash JP, Townsend RR, Ojo A, Roy-Chaudhury A, Go AS, Joffe M, He J, Balakrishnan VS, Kimmel PL, Kusek JW, Raj DS (2016) Inflammation and progression of CKD: the CRIC Study. Clin J Am Soc Nephrol 11:1546–1556PubMedPubMedCentralCrossRef
9.
Silverstein DM (2009) Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol 24:1445–1452PubMedCrossRef
10.
Lewis B, Mukewar S, Lopez R, Brzezinski A, Hall P, Shen B (2013) Frequency and risk factors of renal insufficiency in inflammatory bowel disease inpatients. Inflamm Bowel Dis 19:1846–1851PubMedCrossRef
11.
Casén C, Vebø HC, Sekelja M, Hegge FT, Karlsson MK, Ciemniejewska E, Dzankovic S, Frøyland C, Nestestog R, Engstrand L, Munkholm P, Nielsen OH, Rogler G, Simrén M, Öhman L, Vatn MH, Rudi K (2015) Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther 42:71–83PubMedPubMedCentralCrossRef
12.
Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL (2013) Chronic kidney disease alters intestinal microbial flora. Kidney Int 83:308–315PubMedCrossRef
13.
Mahmoodpoor F, Rahbar Saadat Y, Barzegari A, Ardalan M, Zununi Vahed S (2017) The impact of gut microbiota on kidney function and pathogenesis. Biomed Pharmacother 93:412–419PubMedCrossRef
14.
Jakobsson HE, Rodriguez-Pineiro AM, Schutte A, Ermund A, Boysen P, Bemark M, Sommer F, Backhed F, Hansson GC, Johansson ME (2015) The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep 16:164–177PubMedCrossRef
15.
16.
Shi K, Wang F, Jiang H, Liu H, Wei M, Wang Z, Xie L (2014) Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 59:2109–2117PubMedCrossRef
17.
Poveda J, Sanchez-Nino MD, Glorieux G, Sanz AB, Egido J, Vanholder R, Ortiz A (2014) p-Cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol Dial Transplant 29:56–64PubMedCrossRef
18.
Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND (2014) Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 39:230–237PubMedPubMedCentralCrossRef
19.
Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241–259PubMedCrossRef
20.
Truong LD, Trostel J, Garcia GE (2015) Absence of nicotinic acetylcholine receptor alpha7 subunit amplifies inflammation and accelerates onset of fibrosis: an inflammatory kidney model. FASEB J 29:3558–3570PubMedPubMedCentralCrossRef
21.
Ohland CL, Macnaughton WK (2010) Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298:G807–G819CrossRef
22.
Barrett E, Ross RP, O’Toole PW, Fitzgerald GF, Stanton C (2012) gamma-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol 113:411–417PubMedCrossRef
23.
Sobko T, Huang L, Midtvedt T, Norin E, Gustafsson LE, Norman M, Jansson EA, Lundberg JO (2006) Generation of NO by probiotic bacteria in the gastrointestinal tract. Free Radic Biol Med 41:985–991PubMedCrossRef
24.
de Andrade JAA, Gayer CRM, Nogueira NPA, Paes MC, Bastos V, Neto J, Alves SC Jr, Coelho RM, da Cunha M, Gomes RN, Aguila MB, Mandarim-de-Lacerda CA, Bozza PT, da Cunha S (2014) The effect of thiamine deficiency on inflammation, oxidative stress and cellular migration in an experimental model of sepsis. J Inflamm (Lond) 11:11CrossRef
25.
26.
Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF (2011) Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 108:16050–16055PubMedCrossRef
27.
Vaziri ND, Zhao YY, Pahl MV (2016) Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant 31:737–746CrossRef
28.
Uy N, Graf L, Lemley K, Kaskel F (2015) Effects of gluten-free, dairy-free diet on childhood nephrotic syndrome and gut microbiota. Pediatr Res 77:252–255PubMedCrossRef
29.
Mu Q, Zhang H, Liao X, Lin K, Liu H, Edwards MR, Ahmed SA, Yuan R, Li L, Cecere TE, Branson DB, Kirby JL, Goswami P, Leeth CM, Read KA, Oestreich KJ, Vieson MD, Reilly CM, Luo XM (2017) Control of lupus nephritis by changes of gut microbiota. Microbiome 5:73PubMedPubMedCentralCrossRef
30.
Reigstad CS, Lunden GO, Felin J, Backhed F (2009) Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLoS ONE 4:e5842PubMedPubMedCentralCrossRef
31.
Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, Flint HJ (2000) Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol 66:1654–1661PubMedPubMedCentralCrossRef
32.
Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, Zhang W, Weldon R, Auguste K, Yang L, Liu X, Chen L, Yang X, Zhu B, Cai J (2017) Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 5:14PubMedPubMedCentralCrossRef
33.
Pushpanathan P, Srikanth P, Seshadri KG, Selvarajan S, Pitani RS, Kumar TD, Janarthanan R (2016) Gut microbiota in type 2 diabetes individuals and correlation with monocyte chemoattractant protein1 and interferon gamma from patients attending a Tertiary Care Centre in Chennai, India. Indian J Endocrinol Metab 20:523–530PubMedPubMedCentralCrossRef
34.
Kohn FR, Kung AH (1995) Role of endotoxin in acute inflammation induced by gram-negative bacteria: specific inhibition of lipopolysaccharide-mediated responses with an amino-terminal fragment of bactericidal/permeability-increasing protein. Infect Immun 63:333–339PubMedPubMedCentral
35.
Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL (2013) Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19:576–585PubMedPubMedCentralCrossRef
36.
Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K (2011) Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331:337–341PubMedCrossRef
37.
Sun CY, Hsu HH, Wu MS (2013) p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant 28:70–78PubMedCrossRef
38.
Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL (2015) Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116:448–455PubMedCrossRef
39.
Toyohara T, Suzuki T, Morimoto R, Akiyama Y, Souma T, Shiwaku HO, Takeuchi Y, Mishima E, Abe M, Tanemoto M, Masuda S, Kawano H, Maemura K, Nakayama M, Sato H, Mikkaichi T, Yamaguchi H, Fukui S, Fukumoto Y, Shimokawa H, Inui K-i, Terasaki T, Goto J, Ito S, Hishinuma T, Rubera I, Tauc M, Fujii-Kuriyama Y, Yabuuchi H, Moriyama Y, Soga T, Abe T (2009) SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol 20:2546–2555PubMedPubMedCentralCrossRef
40.
Okada K, Takahashi Y, Okawa E, Onishi Y, Hagi C, Aoki K, Shibahara H, Higuchi T, Nagura Y, Kanmatsuse K, Takahashi S (2001) Relationship between insulin resistance and uremic toxins in the gastrointestinal tract. Nephron 88:384–386PubMedCrossRef
41.
Bansal T, Alaniz RC, Wood TK, Jayaraman A (2010) The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc Natl Acad Sci USA 107:228–233PubMedCrossRef
42.
Wong X, Carrasco-Pozo C, Escobar E, Navarrete P, Blachier F, Andriamihaja M, Lan A, Tomé D, Cires MJ, Pastene E, Gotteland M (2016) Deleterious effect of p-cresol on human colonic epithelial cells prevented by proanthocyanidin-containing polyphenol extracts from fruits and proanthocyanidin bacterial metabolites. J Agric Food Chem 64:3574–3583PubMedCrossRef
43.
Durgan DJ, Ganesh BP, Cope JL, Ajami NJ, Phillips SC, Petrosino JF, Hollister EB, Bryan RM (2016) Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension 67:469–474PubMedCrossRef
44.
Adnan S, Nelson JW, Ajami NJ, Venna VR, Petrosino JF, Bryan RM, Durgan DJ (2017) Alterations in the gut microbiota can elicit hypertension in rats. Physiol Genom 49:96CrossRef
45.
Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V, Cole-Jeffrey CT, Lobaton GO, Stewart DC, Rubiano A, Simmons CS, Garcia-Pereira F, Johnson RD, Pepine CJ, Raizada MK (2017) Hypertension-linked pathophysiological alterations in the gut. Circ Res 120:312–323PubMedCrossRef
46.
Griffiths EA, Duffy LC, Schanbacher FL, Qiao H, Dryja D, Leavens A, Rossman J, Rich G, Dirienzo D, Ogra PL (2004) In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci 49:579–589PubMedCrossRef
47.
48.
Juraschek SP, Bower JK, Selvin E, Subash Shantha GP, Hoogeveen RC, Ballantyne CM, Young JH (2015) Plasma lactate and incident hypertension in the atherosclerosis risk in communities study. Am J Hypertens 28:216–224PubMedCrossRef
49.
Saemann MD, Bohmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, Stockl J, Horl WH, Zlabinger GJ (2000) Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 14:2380–2382PubMedCrossRef
50.
Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ (2007) Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 293:E1289–E1295CrossRef
51.
Ito WD, Lund N, Sager H, Becker W, Wenzel U (2015) Differential impact of diabetes mellitus type II and arterial hypertension on collateral artery growth and concomitant macrophage accumulation. Vasa 44:31–41PubMedCrossRef
52.
Liu KX, Chen SQ, Huang WQ, Li YS, Irwin MG, Xia Z (2008) Propofol pretreatment reduces ceramide production and attenuates intestinal mucosal apoptosis induced by intestinal ischemia/reperfusion in rats. Anesth Analg 107:1884–1891PubMedCrossRef
53.
Wang F, Li Q, He Q, Geng Y, Tang C, Wang C, Li J (2013) Temporal variations of the ileal microbiota in intestinal ischemia and reperfusion. Shock 39:96–103PubMedCrossRef
54.
Peng J, Narasimhan S, Marchesi JR, Benson A, Wong FS, Wen L (2014) Long term effect of gut microbiota transfer on diabetes development. J Autoimmun 53:85–94PubMedPubMedCentralCrossRef
55.
Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:913–916.e917PubMedCrossRef
56.
Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, Piemonti L, Pastore MR, Paroni R (2006) Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 49:2824–2827PubMedCrossRef
57.
Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:1091–1103PubMedPubMedCentralCrossRef
58.
Kopecny J, Zorec M, Mrazek J, Kobayashi Y, Marinsek-Logar R (2003) Butyrivibrio hungatei sp. nov. and Pseudobutyrivibrio xylanivorans sp. nov., butyrate-producing bacteria from the rumen. Int J Syst Evol Microbiol 53:201–209PubMedCrossRef
59.
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto J-M, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60PubMedCrossRef
60.
Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, Casella G, Drew JC, Ilonen J, Knip M, Hyoty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH, Schatz D, Atkinson MA, Triplett EW (2011) Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE 6:e25792PubMedPubMedCentralCrossRef
61.
Hague A, Butt AJ, Paraskeva C (1996) The role of butyrate in human colonic epithelial cells: an energy source or inducer of differentiation and apoptosis? Proc Nutr Soc 55:937–943PubMedCrossRef
62.
Peng L, Li Z-R, Green RS, Holzman IR, Lin J (2009) Butyrate Enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in caco-2 cell monolayers. J Nutr 139:1619–1625PubMedPubMedCentralCrossRef
63.
Burger-van Paassen N, Vincent A, Puiman PJ, van der Sluis M, Bouma J, Boehm G, van Goudoever JB, van Seuningen I, Renes IB (2009) The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J 420:211–219PubMedCrossRef
64.
Deplancke B, Vidal O, Ganessunker D, Donovan SM, Mackie RI, Gaskins HR (2002) Selective growth of mucolytic bacteria including Clostridium perfringens in a neonatal piglet model of total parenteral nutrition. Am J Clin Nutr 76:1117–1125PubMedCrossRef
65.
Wright DP, Knight CG, Parkar SG, Christie DL, Roberton AM (2000) Cloning of a mucin-desulfating sulfatase gene from prevotella strain RS2 and its expression using a bacteroides recombinant system. J Bacteriol 182:3002–3007PubMedPubMedCentralCrossRef
66.
Smedley JG, Fisher DJ, Sayeed S, Chakrabarti G, McClane BA (2005) The enteric toxins of Clostridium perfringens. Reviews of physiology, biochemistry and pharmacology. Springer, Berlin, pp 183–204
67.
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti J-F, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761PubMedCrossRef
68.
Nymark M, Pussinen PJ, Tuomainen AM, Forsblom C, Groop P-H, Lehto M, On behalf of the FinnDiane Study Group (2009) Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care 32:1689–1693PubMedPubMedCentralCrossRef
69.
Tai N, Peng J, Liu F, Gulden E, Hu Y, Zhang X, Chen L, Wong FS, Wen L (2016) Microbial antigen mimics activate diabetogenic CD8 T cells in NOD mice. J Exp Med 213:2129–2146PubMedPubMedCentralCrossRef
70.
Dolpady J, Sorini C, Di Pietro C, Cosorich I, Ferrarese R, Saita D, Clementi M, Canducci F, Falcone M (2016) Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase-enriched tolerogenic intestinal environment. J Diabetes Res 2016:7569431PubMedCrossRef
71.
Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, Mazmanian SK (2011) The Toll-like receptor pathway establishes commensal gut colonization. Science 332:974–977PubMedPubMedCentralCrossRef
72.
Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446–450PubMedCrossRef
73.
LeBlanc JG, Laino JE, del Valle MJ, Vannini V, van Sinderen D, Taranto MP, de Valdez GF, de Giori GS, Sesma F (2011) B-group vitamin production by lactic acid bacteria—current knowledge and potential applications. J Appl Microbiol 111:1297–1309PubMedCrossRef
74.
Jayashree S, Jayaraman K, Kalaichelvan G (2010) Isolation, screening and characterization of riboflavin producing lactic acid bacteria from Katpadi, Vellore district. Recent Res Sci Technol 2:83–88
75.
Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, Williamson NA, Purcell AW, Dudek NL, McConville MJ, O‘Hair RAJ, Khairallah GN, Godfrey DI, Fairlie DP, Rossjohn J, McCluskey J (2012) MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491:717–723PubMedCrossRef
76.
Ruijing X, Mengjun W, Xiaoling Z, Shu P, Mei W, Yingcheng Z, Yuling H, Jinquan T (2012) Jalpha33 + MAIT cells play a protective role in TNBS induced intestinal inflammation. Hepatogastroenterology 59:762–767PubMed
77.
Qiao Y-c, Shen J, He L, Hong X-z, Tian F, Pan Y-h, Liang L, Zhang X-x, Zhao H-l (2016) Changes of regulatory T cells and of proinflammatory and immunosuppressive cytokines in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes Res 2016:3694957PubMedPubMedCentralCrossRef
78.
Badami E, Sorini C, Coccia M, Usuelli V, Molteni L, Bolla AM, Scavini M, Mariani A, King C, Bosi E, Falcone M (2011) Defective differentiation of regulatory FoxP3(+) T cells by small-intestinal dendritic cells in patients with type 1 diabetes. Diabetes 60:2120–2124PubMedPubMedCentralCrossRef
79.
Wen L, Wong FS (2017) Dietary short-chain fatty acids protect against type 1 diabetes. Nat Immunol 18:484–486PubMedCrossRef
80.
Shi G, Sun C, Gu W, Yang M, Zhang X, Zhai N, Lu Y, Zhang Z, Shou P, Zhang Z, Ning G (2014) Free fatty acid receptor 2, a candidate target for type 1 diabetes, induces cell apoptosis through ERK signaling. J Mol Endocrinol 53:367–380PubMedCrossRef
81.
McNelis JC, Lee YS, Mayoral R, van der Kant R, Johnson AM, Wollam J, Olefsky JM (2015) GPR43 potentiates beta-cell function in obesity. Diabetes 64:3203–3217PubMedPubMedCentralCrossRef
82.
Venter CS, Vorster HH, Cummings JH (1990) Effects of dietary propionate on carbohydrate and lipid metabolism in healthy volunteers. Am J Gastroenterol 85:549–553PubMed
83.
Villa SR, Priyadarshini M, Fuller MH, Bhardwaj T, Brodsky MR, Angueira AR, Mosser RE, Carboneau BA, Tersey SA, Mancebo H, Gilchrist A, Mirmira RG, Gannon M, Layden BT (2016) Loss of free fatty acid receptor 2 leads to impaired islet mass and beta cell survival. Sci Rep 6:28159PubMedPubMedCentralCrossRef
84.
Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:364–371PubMedPubMedCentralCrossRef
85.
Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA (1996) Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients. Diabetes Care 19:580–586PubMedCrossRef
86.
Grigoropoulou P, Eleftheriadou I, Zoupas C, Diamanti-Kandarakis E, Tentolouris N (2013) Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance. Curr Diabetes Rev 9:412–417PubMedCrossRef
87.
Holz GG (2004) Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53:5–13PubMedPubMedCentralCrossRef
88.
Cobianchi L, Fornoni A, Pileggi A, Molano RD, Sanabria NY, Gonzalez-Quintana J, Bocca N, Marzorati S, Zahr E, Hogan AR, Ricordi C, Inverardi L (2008) Riboflavin inhibits IL-6 expression and p38 activation in islet cells. Cell Transplant 17:559–566PubMedCrossRef
89.
Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL (2004) Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J Immunol 173:5298–5304PubMedCrossRef
90.
Marques TM, Patterson E, Wall R, O’Sullivan O, Fitzgerald GF, Cotter PD, Dinan TG, Cryan JF, Ross RP, Stanton C (2016) Influence of GABA and GABA-producing Lactobacillus brevis DPC 6108 on the development of diabetes in a streptozotocin rat model. Benef Microbes 7:409–420PubMedCrossRef
91.
Joshi A, Woodman OL (2012) Increased nitric oxide activity compensates for increased oxidative stress to maintain endothelial function in rat aorta in early type 1 diabetes. Naunyn-Schmiedeberg’s Arch Pharmacol 385:1083–1094CrossRef
92.
Aldahmash BA, El-Nagar DM, Ibrahim KE (2016) Attenuation of hepatotoxicity and oxidative stress in diabetes STZ-induced type 1 by biotin in Swiss albino mice. Saudi J Biol Sci 23:311–317PubMedCrossRef
93.
Peña AS, Maftei O, Dowling K, Gent R, Wiltshire E, MacKenzie K, Couper J (2013) Folate fortification and supplementation do not provide vascular health benefits in type 1 diabetes. J Pediatr 163:255–260PubMedCrossRef
94.
Wang XX, Jiang T, Shen Y, Caldas Y, Miyazaki-Anzai S, Santamaria H, Urbanek C, Solis N, Scherzer P, Lewis L, Gonzalez FJ, Adorini L, Pruzanski M, Kopp JB, Verlander JW, Levi M (2010) Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 59:2916–2927PubMedPubMedCentralCrossRef
95.
Zhu C, Fuchs CD, Halilbasic E, Trauner M (2016) Bile acids in regulation of inflammation and immunity: friend or foe? Clin Exp Rheumatol 34:25–31PubMed
96.
Moynes DM, Lucas GH, Beyak MJ, Lomax AE (2014) Effects of inflammation on the innervation of the colon. Toxicol Pathol 42:111–117PubMedCrossRef
97.
Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW, Smythe GA (1992) The effects of sympathetic nervous system activation and psychological stress on glucose metabolism and blood pressure in subjects with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:835–843PubMedCrossRef
98.
Beilharz JE, Kaakoush NO, Maniam J, Morris MJ (2016) The effect of short-term exposure to energy-matched diets enriched in fat or sugar on memory, gut microbiota and markers of brain inflammation and plasticity. Brain Behav Immun 57:304–313PubMedCrossRef
99.
Watkins CC, Sawa A, Jaffrey S, Blackshaw S, Barrow RK, Snyder SH, Ferris CD (2000) Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 106:373–384PubMedPubMedCentralCrossRef
100.
Ordog T, Takayama I, Cheung WK, Ward SM, Sanders KM (2000) Remodeling of networks of interstitial cells of cajal in a murine model of diabetic gastroparesis. Diabetes 49:1731–1739PubMedCrossRef
101.
Virally-Monod M, Tielmans D, Kevorkian JP, Bouhnik Y, Flourie B, Porokhov B, Ajzenberg C, Warnet A, Guillausseau PJ (1998) Chronic diarrhoea and diabetes mellitus: prevalence of small intestinal bacterial overgrowth. Diabetes Metab 24:530–536PubMed
102.
Wang L, Li P, Tang Z, Yan X, Feng B (2016) Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci Rep 6:33251PubMedPubMedCentralCrossRef
103.
Sun G, Yin Z, Liu N, Bian X, Yu R, Su X, Zhang B, Wang Y (2017) Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity. Biochem Biophys Res Commun 493:964–970PubMedCrossRef
104.
Wu B, Jiang H, He Q, Wang M, Xue J, Liu H, Shi K, Wei M, Liang S, Zhang L (2017) Liquid chromatography/mass spectrometry reveals the effect of lactobacillus treatment on the faecal metabolite profile of rats with chronic renal failure. Nephron 135:156–166PubMedCrossRef
105.
Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A, Mackay CR, Kaye DM (2017) High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 135:964–977PubMedCrossRef
106.
Stewart DC, Rubiano A, Santisteban MM, Shenoy V, Qi Y, Pepine CJ, Raizada MK, Simmons CS (2016) Hypertension-linked mechanical changes of rat gut. Acta Biomater 45:296–302PubMedPubMedCentralCrossRef
107.
Li X, Wang E, Yin B, Fang D, Chen P, Wang G, Zhao J, Zhang H, Chen W (2017) Effects of Lactobacillus casei CCFM419 on insulin resistance and gut microbiota in type 2 diabetic mice. Benef Microbes 8:421–432PubMedCrossRef
108.
Singh S, Sharma RK, Malhotra S, Pothuraju R, Shandilya UK (2017) Lactobacillus rhamnosus NCDC17 ameliorates type-2 diabetes by improving gut function, oxidative stress and inflammation in high-fat-diet fed and streptozotocintreated rats. Benef Microbes 8:243–255PubMedCrossRef
109.
Yacoub R, Nugent M, Cai W, Nadkarni GN, Chaves LD, Abyad S, Honan AM, Thomas SA, Zheng W, Valiyaparambil SA, Bryniarski MA, Sun Y, Buck M, Genco RJ, Quigg RJ, He JC, Uribarri J (2017) Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial. PLoS ONE 12:e0184789PubMedPubMedCentralCrossRef
110.
Rossi M, Johnson DW, Morrison M, Pascoe EM, Coombes JS, Forbes JM, Szeto CC, McWhinney BC, Ungerer JP, Campbell KL (2016) Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin J Am Soc Nephrol 11:223–231PubMedPubMedCentralCrossRef
111.
Fangmann D, Theismann EM, Turk K, Schulte DM, Relling I, Hartmann K, Keppler JK, Knipp JR, Rehman A, Heinsen FA, Franke A, Lenk L, Freitag-Wolf S, Appel E, Gorb S, Brenner C, Seegert D, Waetzig GH, Rosenstiel P, Schreiber S, Schwarz K, Laudes M (2017) Targeted microbiome intervention by microencapsulated delayed-release niacin beneficially affects insulin sensitivity in humans. Diabetes Care. https://​doi.​org/​10.​2337/​dc17-1967 PubMedCrossRef
112.
Soleimani A, Zarrati Mojarrad M, Bahmani F, Taghizadeh M, Ramezani M, Tajabadi-Ebrahimi M, Jafari P, Esmaillzadeh A, Asemi Z (2017) Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney Int 91:435–442PubMedCrossRef
113.
Balfego M, Canivell S, Hanzu FA, Sala-Vila A, Martinez-Medina M, Murillo S, Mur T, Ruano EG, Linares F, Porras N, Valladares S, Fontalba M, Roura E, Novials A, Hernandez C, Aranda G, Siso-Almirall A, Rojo-Martinez G, Simo R, Gomis R (2016) Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naive patients with type 2 diabetes: a pilot randomized trial. Lipids Health Dis 15:78PubMedPubMedCentralCrossRef
114.
Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L (2010) Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 362:590–599PubMedPubMedCentralCrossRef
115.
Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334:105–108PubMedPubMedCentralCrossRef
116.
Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR (2009) Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29:508–518PubMedCrossRef
117.
Klinder A, Shen Q, Heppel S, Lovegrove JA, Rowland I, Tuohy KM (2016) Impact of increasing fruit and vegetables and flavonoid intake on the human gut microbiota. Food Funct 7:1788–1796PubMedCrossRef
118.
Vaziri ND, Liu SM, Lau WL, Khazaeli M, Nazertehrani S, Farzaneh SH, Kieffer DA, Adams SH, Martin RJ (2014) High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS ONE 9:e114881PubMedPubMedCentralCrossRef
119.
Kieffer DA, Piccolo BD, Vaziri ND, Liu S, Lau WL, Khazaeli M, Nazertehrani S, Moore ME, Marco ML, Martin RJ, Adams SH (2016) Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats. Am J Physiol Renal Physiol 310:F857–F871CrossRef
120.
Richter CK, Skulas-Ray AC, Champagne CM, Kris-Etherton PM (2015) Plant protein and animal proteins: do they differentially affect cardiovascular disease risk? Adv Nutr 6:712–728PubMedPubMedCentralCrossRef
121.
Krishnamurthy VM, Wei G, Baird BC, Murtaugh M, Chonchol MB, Raphael KL, Greene T, Beddhu S (2012) High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 81:300–306PubMedCrossRef
122.
Pavan M (2016) Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease. Minerva Urol Nefrol 68:222–226PubMed
123.
Aliasgharzadeh A, Dehghan P, Gargari BP, Asghari-Jafarabadi M (2015) Resistant dextrin, as a prebiotic, improves insulin resistance and inflammation in women with type 2 diabetes: a randomised controlled clinical trial. Br J Nutr 113:321–330PubMedCrossRef
124.
Torsdottir I, Alpsten M, Holm G, Sandberg AS, Tolli J (1991) A small dose of soluble alginate-fiber affects postprandial glycemia and gastric emptying in humans with diabetes. J Nutr 121:795–799PubMedCrossRef
125.
Sola R, Godas G, Ribalta J, Vallve JC, Girona J, Anguera A, Ostos M, Recalde D, Salazar J, Caslake M, Martin-Lujan F, Salas-Salvado J, Masana L (2007) Effects of soluble fiber (Plantago ovata husk) on plasma lipids, lipoproteins, and apolipoproteins in men with ischemic heart disease. Am J Clin Nutr 85:1157–1163PubMedCrossRef
126.
Eliasson K, Ryttig KR, Hylander B, Rossner S (1992) A dietary fibre supplement in the treatment of mild hypertension. A randomized, double-blind, placebo-controlled trial. J Hypertens 10:195–199PubMedCrossRef
127.
He J, Streiffer RH, Muntner P, Krousel-Wood MA, Whelton PK (2004) Effect of dietary fiber intake on blood pressure: a randomized, double-blind, placebo-controlled trial. J Hypertens 22:73–80PubMedCrossRef
128.
Zhu HL, Liu YL, Xie XL, Huang JJ, Hou YQ (2013) Effect of L-arginine on intestinal mucosal immune barrier function in weaned pigs after Escherichia coli LPS challenge. Innate Immun 19:242–252PubMedCrossRef
129.
Tome-Carneiro J, Visioli F (2016) Polyphenol-based nutraceuticals for the prevention and treatment of cardiovascular disease: review of human evidence. Phytomedicine 23:1145–1174PubMedCrossRef
130.
Hawrelak JA, Cattley T, Myers SP (2009) Essential oils in the treatment of intestinal dysbiosis: a preliminary in vitro study. Altern Med Rev 14:380–384PubMed
131.
Monda V, Villano I, Messina A, Valenzano A, Esposito T, Moscatelli F, Viggiano A, Cibelli G, Chieffi S, Monda M, Messina G (2017) Exercise modifies the gut microbiota with positive health effects. Oxid Med Cell Longev 2017:3831972PubMedPubMedCentralCrossRef
132.
Gobel RJ, Larsen N, Jakobsen M, Molgaard C, Michaelsen KF (2012) Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome. J Pediatr Gastroenterol Nutr 55:673–678PubMedCrossRef
133.
Lamprecht M, Bogner S, Schippinger G, Steinbauer K, Fankhauser F, Hallstroem S, Schuetz B, Greilberger JF (2012) Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr 9:45PubMedPubMedCentralCrossRef
134.
Miranda Alatriste PV, Urbina Arronte R, Gomez Espinosa CO, Espinosa Cuevas MDLA (2014) Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp 29:582–590PubMed
135.
Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Delano B, Goldfarb DS, Tam P, Rao AV, Anteyi E, Musso CG (2010) Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 27:634–647PubMedCrossRef
136.
Abbasi B, Ghiasvand R, Mirlohi M (2017) Kidney function improvement by soy milk containing Lactobacillus plantarum A7 in type 2 diabetic patients with nephropathy: a double-blinded randomized controlled trial. Iran J Kidney Dis 11:36–43PubMed
137.
Khalesi S, Sun J, Buys N, Jayasinghe R (2014) Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 64:897–903PubMedCrossRef
138.
Yacoub R, Kaji D, Patel SN, Simoes PK, Busayavalasa D, Nadkarni GN, He JC, Coca SG, Uribarri J (2016) Association between probiotic and yogurt consumption and kidney disease: insights from NHANES. Nutr J 15:10PubMedPubMedCentralCrossRef
139.
Uusitalo U, Liu X, Yang J, Aronsson CA, Hummel S, Butterworth M, Lernmark Å, Rewers M, Hagopian W, She J-X, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer J, Norris JM, Virtanen SM (2016) Association of early exposure of probiotics and islet autoimmunity in the TEDDY Study. JAMA Pediatr 170:20–28PubMedPubMedCentralCrossRef
140.
Kasinska MA, Drzewoski J (2015) Effectiveness of probiotics in type 2 diabetes: a meta-analysis. Pol Arch Med Wewn 125:803–813PubMed
141.
Brugere JF, Borrel G, Gaci N, Tottey W, O’Toole PW, Malpuech-Brugere C (2014) Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut Microbes 5:5–10PubMedCrossRef
142.
Prakash S, Chang TM (1996) Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat Med 2:883–887PubMedCrossRef
143.
Zhao S, Liu W, Wang J, Shi J, Sun Y, Wang W, Ning G, Liu R, Hong J (2017) Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice. J Mol Endocrinol 58:1–14PubMedCrossRef
144.
Zeng YQ, Dai Z, Lu F, Lu Z, Liu X, Chen C, Qu P, Li D, Hua Z, Qu Y, Zou C (2016) Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease. Oncotarget 7:17468–17478PubMedPubMedCentral
145.
Napolitano A, Miller S, Nicholls AW, Baker D, Van Horn S, Thomas E, Rajpal D, Spivak A, Brown JR, Nunez DJ (2014) Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS ONE 9:e100778PubMedPubMedCentralCrossRef
146.
Mishima E, Fukuda S, Shima H, Hirayama A, Akiyama Y, Takeuchi Y, Fukuda NN, Suzuki T, Suzuki C, Yuri A, Kikuchi K, Tomioka Y, Ito S, Soga T, Abe T (2015) Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol 26:1787–1794PubMedCrossRef
147.
Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S (1997) The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 62:S23–S28
148.
Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Donate-Correa J, Cazana-Perez V, Garcia-Perez J (2011) Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol 6:2272–2279PubMedPubMedCentralCrossRef
149.
Ellis RJ, Small DM, Vesey DA, Johnson DW, Francis R, Vitetta L, Gobe GC, Morais C (2016) Indoxyl sulphate and kidney disease: causes, consequences and interventions. Nephrology (Carlton) 21:170–177CrossRef
150.
Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D (2017) Gut microbiome in chronic kidney disease: challenges and opportunities. Transl Res 179:24–37PubMedCrossRef
Metadata
Title
The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus
Authors
Mehmet Kanbay
Emine M. Onal
Baris Afsar
Tuncay Dagel
Aslihan Yerlikaya
Adrian Covic
Nosratola D. Vaziri
Publication date
01-08-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 8/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-1873-2

Other articles of this Issue 8/2018

International Urology and Nephrology 8/2018 Go to the issue

Nephrology - Original Paper

The effect of periodontal disease treatment in patients with continuous ambulatory peritoneal dialysis

Nephrology - Letter to the editor

The prevalence of hepatitis C and B among patients on hemodialysis and on renal transplantation waiting list in Poland has significantly decreased during the last 10 years

Nephrology - Review

A holistic approach to factors affecting depression in haemodialysis patients

Urology - Original Paper

Histopathologic and molecular comparative analyses of intravesical Aurora kinase-A inhibitor Alisertib with bacillus Calmette–Guérin on precancerous lesions of bladder in a rat model

Urology - Original Paper

A novel method for prediction of stone composition: the average and difference of Hounsfield units and their cut-off values

Urology - Original Paper

Dynamic assessment of human sperm DNA damage I: the effect of seminal plasma-sperm co-incubation after ejaculation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits